Mohamad Mahjoor1, Hamed Afkhami2, Mohammad Najafi3, Atieh Nasr4, Samaneh Khorrami5. 1. Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. 2. Department of Medical Microbiology, Faculty of Medicine, Shahed University of Medical Sciences, Tehran, Iran. 3. Department of Biochemistry, Faculty of Medical, Iran University of Medical Sciences, Tehran, Iran. 4. Department of Biochemistry, Islamic Azad University of Najafabad, Esfahan, Iran. 5. Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. khorami.s@iums.ac.ir.
Abstract
INTRODUCTION: Colorectal cancer (CRC) is the third most prevalent cancer and the second significant cause of cancer-associated death worldwide. The microRNA-30 is a substantial member of the miRNA family and plays a vital role in expanding several cancers. This microRNA potentially targets interleukin 6 as an inflammatory cytokine in CRC. MATERIALS AND METHODS: MSCs were isolated and identified from mice bone marrow and then transduced with lentiviruses containing miR-30C. Transfected MSCs were collected to evaluate IL-6 levels, CT-26 cells were also co-cultured with MSCs, and the effect of apoptosis and IL-6 on the supernatant was assessed. RESULTS: Our result showed the expression of IL-6 mRNA and the level of protein were decreased in the supernatant of miR-30-transduced MSC cells compared to the control group. In addition, the rate of apoptosis was assessed, and the obtained data revealed the induction of apoptosis in CT-26 cells when they are in the vicinity of miR-30c-transduced MSCs. DISCUSSION AND CONCLUSION: We demonstrated that downregulation of miR-30c was significantly correlated with CRC progression and survival. So, the present study elucidated the anticancer effects of miR-30c in CRC and presented a novel target for CRC therapy.
INTRODUCTION: Colorectal cancer (CRC) is the third most prevalent cancer and the second significant cause of cancer-associated death worldwide. The microRNA-30 is a substantial member of the miRNA family and plays a vital role in expanding several cancers. This microRNA potentially targets interleukin 6 as an inflammatory cytokine in CRC. MATERIALS AND METHODS: MSCs were isolated and identified from mice bone marrow and then transduced with lentiviruses containing miR-30C. Transfected MSCs were collected to evaluate IL-6 levels, CT-26 cells were also co-cultured with MSCs, and the effect of apoptosis and IL-6 on the supernatant was assessed. RESULTS: Our result showed the expression of IL-6 mRNA and the level of protein were decreased in the supernatant of miR-30-transduced MSC cells compared to the control group. In addition, the rate of apoptosis was assessed, and the obtained data revealed the induction of apoptosis in CT-26 cells when they are in the vicinity of miR-30c-transduced MSCs. DISCUSSION AND CONCLUSION: We demonstrated that downregulation of miR-30c was significantly correlated with CRC progression and survival. So, the present study elucidated the anticancer effects of miR-30c in CRC and presented a novel target for CRC therapy.
Authors: Jessica Bockhorn; Kathy Yee; Ya-Fang Chang; Aleix Prat; Dezheng Huo; Chika Nwachukwu; Rachel Dalton; Simo Huang; Kaitlin E Swanson; Charles M Perou; Olufunmilayo I Olopade; Michael F Clarke; Geoffrey L Greene; Huiping Liu Journal: Breast Cancer Res Treat Date: 2012-12-07 Impact factor: 4.872